{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:36:07Z","timestamp":1791275767380,"version":"4.1.0"},"reference-count":224,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.pharmthera.2009.06.005","type":"journal-article","created":{"date-parts":[[2009,6,27]],"date-time":"2009-06-27T04:36:10Z","timestamp":1246077370000},"page":"44-56","source":"Crossref","is-referenced-by-count":105,"title":["Gut hormones: Implications for the treatment of obesity"],"prefix":"10.1016","volume":"124","author":[{"given":"Marianne T.","family":"Neary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Batterham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2009.06.005_bib1","unstructured":"7TM Pharma (2008a). Results from a phase I\/II clinical study with the drug candidate Obinepitide for the treatment of obesity. 7TM Pharma: Press release November 28, 2007. Retrieved June 2nd, 2009, from http:\/\/www.7tm.com\/News\/News_Archive.aspx?M=News&PID=45&NewsID=9"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib2","unstructured":"7TM Pharma (2008b). TM Pharma has initiated phase I\/IIa clinical trial with TM30339 for the treatment of obesity and related metabolic disorders. 7TM Pharma: Press Release. September 2nd, 2008. Retrieved June 2nd, 2009 from http:\/\/www.7tm.com\/News\/News_Archive.aspx?M=News&PID=45&NewsID=45"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib3","unstructured":"7TM Pharma (n.d.). Obinepitide. 7TM Pharma Retrieved June 2nd, 2009, from http:\/\/www.7tm.com\/R-D\/Metabolic_Disorders\/Obinepitide.aspx"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brainres.2005.03.011","article-title":"The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal\u2013brainstem\u2013hypothalamic pathway","volume":"1044","author":"Abbott","year":"2005","journal-title":"Brain Res"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2009.06.005_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.brainres.2005.02.065","article-title":"Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake","volume":"1043","author":"Abbott","year":"2005","journal-title":"Brain Res"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1079\/BJN20041335","article-title":"Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects","volume":"93","author":"Adam","year":"2005","journal-title":"Br J Nutr"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib7","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/oby.2005.80","article-title":"Decreased glucagon-like peptide 1 release after weight loss in overweight\/obese subjects","volume":"13","author":"Adam","year":"2005","journal-title":"Obes Res"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.06.005_bib8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.17.12.940","article-title":"Distribution and release of human pancreatic polypeptide","volume":"17","author":"Adrian","year":"1976","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/0016-5085(85)90211-2","article-title":"Human distribution and release of a putative new gut hormone, peptide YY","volume":"89","author":"Adrian","year":"1985","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","article-title":"The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men","volume":"45","author":"Agerso","year":"2002","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1381\/096089202321088084","article-title":"Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty","volume":"12","author":"Alvarez Bartolome","year":"2002","journal-title":"Obes Surg"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib13","unstructured":"Amylin Pharmaceuticals Inc. (2007). A pilot study of effects of exenatide on body weight in non-diabetic, obese patients. Clinicaltrials.gov Retrieved June 3rd, 2009, from http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00500370?term=byetta+obesity&rank=2"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib12","unstructured":"Amylin Pharmaceuticals Inc. (2008a). Amylin Pharmaceuticals initiates phase 2B dose-ranging clinical study of pramlintide\/metreleptin combination treatment in obesity. Amylin Pharmaceuticals, Inc.: Press Release May 5, 2009. Retrieved June 2nd, 2009, from http:\/\/investors.amylin.com\/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1139912&highlight="},{"key":"10.1016\/j.pharmthera.2009.06.005_bib14","unstructured":"Amylin Pharmaceuticals Inc. (2008b). Amylin Pharmaceuticals to present novel data on promising obesity pipeline at 2008 Annual Scientific Meeting of The Obesity Society. Amylin Pharmaceuticals, Inc.: Press Release October 1, 2008. Retrieved June 2nd, 2009, from http:\/\/investors.amylin.com\/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1204556&highlight=AC2307"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib15","unstructured":"Amylin Pharmaceuticals Inc. (n.d.). Davalintide (AC2307). Amylin Pharmaceuticals: Pipeline. Retrieved June 2nd, 2009, from http:\/\/www.amylin.com\/pipeline\/pyy336.cfm"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1086\/381717","article-title":"Evidence of a novel quantitative-trait locus for obesity on chromosome 4p in Mexican Americans","volume":"74","author":"Arya","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.06.005_bib17","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0196-9781(99)00155-2","article-title":"Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice","volume":"20","author":"Asakawa","year":"1999","journal-title":"Peptides"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.06.005_bib18","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/gut.52.7.947","article-title":"Antagonism of ghrelin receptor reduces food intake and body weight gain in mice","volume":"52","author":"Asakawa","year":"2003","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib19","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0016-5085(03)00216-6","article-title":"Characterization of the effects of pancreatic polypeptide in the regulation of energy balance","volume":"124","author":"Asakawa","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2009.03.012","article-title":"Metabolic surgery and gut hormones \u2014 a review of bariatric entero-humoral modulation","author":"Ashrafian","year":"2009","journal-title":"Physiol Behav. Epub ahead of print"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.gastro.2004.04.063","article-title":"Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure","volume":"127","author":"Baggio","year":"2004","journal-title":"Gastroenterology"},{"issue":"1-2","key":"10.1016\/j.pharmthera.2009.06.005_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0167-0115(88)90099-7","article-title":"Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs","volume":"21","author":"Baldissera","year":"1988","journal-title":"Regul Pept"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib23","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1124\/jpet.102.034827","article-title":"Extent and direction of ghrelin transport across the blood\u2013brain barrier is determined by its unique primary structure","volume":"302","author":"Banks","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0196-9781(81)80123-4","article-title":"Regional distributions of somatostatin and cholecystokinin-like immunoreactivities in rat and bovine brain","volume":"2","author":"Barden","year":"1981","journal-title":"Peptides"},{"issue":"Suppl 2","key":"10.1016\/j.pharmthera.2009.06.005_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0196-9781(81)90008-5","article-title":"Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities","volume":"2","author":"Bataille","year":"1981","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib26","doi-asserted-by":"crossref","unstructured":"Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., et al. (2002). Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418(6898), 650\u2013654.","DOI":"10.1038\/nature00887"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.06.005_bib27","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa030204","article-title":"Inhibition of food intake in obese subjects by peptide YY3-36","volume":"349","author":"Batterham","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.06.005_bib28","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1210\/jc.2003-030630","article-title":"Pancreatic polypeptide reduces appetite and food intake in humans","volume":"88","author":"Batterham","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cmet.2006.08.001","article-title":"Critical role for peptide YY in protein-mediated satiation and body-weight regulation","volume":"4","author":"Batterham","year":"2006","journal-title":"Cell Metabolism"},{"issue":"7166","key":"10.1016\/j.pharmthera.2009.06.005_bib30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature06212","article-title":"PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans","volume":"450","author":"Batterham","year":"2007","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.lfs.2004.09.001","article-title":"Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats","volume":"76","author":"Beck","year":"2004","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0167-0115(92)90615-2","article-title":"Low hepatic clearance of peptide YY in the perfused rat liver","volume":"37","author":"Beckh","year":"1992","journal-title":"Regul Pept"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib33","doi-asserted-by":"crossref","first-page":"R1149","DOI":"10.1152\/ajpregu.2001.280.4.R1149","article-title":"Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans","volume":"280","author":"Beglinger","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/153537020322800301","article-title":"Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes","volume":"228","author":"Berglund","year":"2003","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0196-9781(93)90138-7","article-title":"Pancreatic polypeptide infusions reduce food intake in Prader\u2013Willi syndrome","volume":"14","author":"Berntson","year":"1993","journal-title":"Peptides"},{"issue":"1-2","key":"10.1016\/j.pharmthera.2009.06.005_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-8993(99)02477-4","article-title":"Brain regions where cholecystokinin suppresses feeding in rats","volume":"860","author":"Blevins","year":"2000","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.npep.2007.11.003","article-title":"PYY transgenic mice are protected against diet-induced and genetic obesity","volume":"42","author":"Boey","year":"2008","journal-title":"Neuropeptides"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1152\/ajpregu.90706.2008","article-title":"The influence of resistance and aerobic exercise on hunger, circulating levels of acylated ghrelin and peptide YY in healthy males","volume":"296","author":"Broom","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.06.005_bib39","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/en.137.7.2968","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0306-4522(01)00474-2","article-title":"Expression of the leptin receptor in rat and human nodose ganglion neurones","volume":"109","author":"Burdyga","year":"2002","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.06.005_bib41","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib42","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2337\/diabetes.39.6.752","article-title":"Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans","volume":"39","author":"Butler","year":"1990","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib43","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1210\/jc.2003-031267","article-title":"Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans","volume":"89","author":"Callahan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"5223","key":"10.1016\/j.pharmthera.2009.06.005_bib44","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1126\/science.7624778","article-title":"Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks","volume":"269","author":"Campfield","year":"1995","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib45","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbrc.2003.10.089","article-title":"Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse","volume":"311","author":"Challis","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.06.005_bib46","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1053\/j.gastro.2009.02.047","article-title":"Subject Standardization, acclimatisation, and sample processing affect gut hormone levels and appetite in humans","volume":"136","author":"Chandarana","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbrc.2006.09.033","article-title":"Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging","volume":"350","author":"Chaudhri","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib48","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/mol.52.6.1164","article-title":"Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors","volume":"52","author":"Chen","year":"1997","journal-title":"Mol Pharmacol"},{"issue":"9600","key":"10.1016\/j.pharmthera.2009.06.005_bib49","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/mol.56.1.235","article-title":"Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product","volume":"56","author":"Christopoulos","year":"1999","journal-title":"Mol Pharmacol"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2009.06.005_bib51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.regpep.2007.09.003","article-title":"Amylin causes anorexigenic effects via the hypothalamus and brain stem in chicks","volume":"146","author":"Cline","year":"2008","journal-title":"Regul Pept"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.06.005_bib52","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1210\/jc.2003-030421","article-title":"Oxyntomodulin suppresses appetite and reduces food intake in humans","volume":"88","author":"Cohen","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"5910","key":"10.1016\/j.pharmthera.2009.06.005_bib53","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/302703a0","article-title":"Rapid development of tolerance to the behavioural actions of cholecystokinin","volume":"302","author":"Crawley","year":"1983","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.physbeh.2006.05.022","article-title":"Ghrelin and the short- and long-term regulation of appetite and body weight","volume":"89","author":"Cummings","year":"2006","journal-title":"Physiol Behav"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.06.005_bib55","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/diabetes.50.8.1714","article-title":"A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans","volume":"50","author":"Cummings","year":"2001","journal-title":"Diabetes"},{"issue":"21","key":"10.1016\/j.pharmthera.2009.06.005_bib56","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1056\/NEJMoa012908","article-title":"Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery","volume":"346","author":"Cummings","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006162.pub2","article-title":"Rimonabant for overweight or obesity","author":"Curioni","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib58","unstructured":"Cytos Biotechnology. (2006). Phase I\/IIa clinical trial with obese individuals shows no effect of CYT009-GhrQb on weight loss. Cytos Biotechnology: Press Release November 7, 2006 Retrieved June 2nd, 2009, from http:\/\/www.cytos.com\/doc\/Cytos_Press_E_061107.pdf"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.06.005_bib59","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1210\/en.142.10.4244","article-title":"Oxyntomodulin inhibits food intake in the rat","volume":"142","author":"Dakin","year":"2001","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib60","doi-asserted-by":"crossref","first-page":"E1173","DOI":"10.1152\/ajpendo.00233.2002","article-title":"Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats","volume":"283","author":"Dakin","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib61","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1210\/en.2003-1338","article-title":"Peripheral oxyntomodulin reduces food intake and body weight gain in rats","volume":"145","author":"Dakin","year":"2004","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib62","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2337\/db06-0473","article-title":"Common genetic variations in CCK, leptin, and leptin receptor genes are associated with specific human eating patterns","volume":"56","author":"de Krom","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/0-306-47920-6_1","article-title":"Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV","volume":"524","author":"de Meester","year":"2003","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.06.005_bib64","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1210\/en.2004-0569","article-title":"Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites","volume":"145","author":"De Vriese","year":"2004","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib65","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/ajcn\/52.3.553","article-title":"Coffee stimulation of cholecystokinin release and gallbladder contraction in humans","volume":"52","author":"Douglas","year":"1990","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1210\/en.2005-0973","article-title":"Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status","volume":"147","author":"Drazen","year":"2006","journal-title":"Endocrinology"},{"issue":"9645","key":"10.1016\/j.pharmthera.2009.06.005_bib67","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib68","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1152\/physrev.00014.2005","article-title":"Cholecystokinin and gastrin receptors","volume":"86","author":"Dufresne","year":"2006","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib69","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12031-007-9007-9","article-title":"Distribution of peripherally injected peptide YY ([125I] PYY (3-36)) and pancreatic polypeptide ([125I] hPP) in the CNS: enrichment in the area postrema","volume":"33","author":"Dumont","year":"2007","journal-title":"J Mol Neurosci"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib70","doi-asserted-by":"crossref","first-page":"E963","DOI":"10.1152\/ajpendo.00527.2003","article-title":"Sleep enhances nocturnal plasma ghrelin levels in healthy subjects","volume":"286","author":"Dzaja","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5 Pt 2","key":"10.1016\/j.pharmthera.2009.06.005_bib71","first-page":"R971","article-title":"Dorsomedial hindbrain participation in cholecystokinin-induced satiety","volume":"251","author":"Edwards","year":"1986","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib72","first-page":"49","article-title":"Amyloidosis of the islets of Langerhans. A restudy of islet hyalin in diabetic and non-diabetic individuals","volume":"38","author":"Ehrlich","year":"1961","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib73","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0196-9781(01)00601-5","article-title":"Distribution of pancreatic polypeptide and peptide YY","volume":"23","author":"Ekblad","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib74","unstructured":"Emisphere Technologies Inc. (2009). Emisphere Technologies reports encouraging data from independent clinical study assessing the effects of oral GLP-1 and PYY3-36, combined with Eligen(R) Technology on appetite suppression. Emisphere Technologies, Inc.: Press Release May 26, 2009 Retrieved June 2nd, 2009, from http:\/\/ir.emisphere.com\/releasedetail.cfm?ReleaseID=385806"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.06.005_bib75","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib76","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.brainres.2008.04.068","article-title":"Caudal brainstem delivery of ghrelin induces fos expression in the nucleus of the solitary tract, but not in the arcuate or paraventricular nuclei of the hypothalamus","volume":"1218","author":"Faulconbridge","year":"2008","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib77","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0196-9781(94)90204-6","article-title":"Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39)","volume":"15","author":"Fehmann","year":"1994","journal-title":"Peptides"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.06.005_bib78","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1210\/jc.2007-2138","article-title":"Hyperghrelinemia precedes obesity in Prader\u2013Willi syndrome","volume":"93","author":"Feigerlova","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib79","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1381\/096089298765554331","article-title":"Changes in measured resting energy expenditure after Roux-en-Y gastric bypass for clinically severe obesity are not related to bypass limb-length","volume":"8","author":"Flancbaum","year":"1998","journal-title":"Obes Surg"},{"issue":"20","key":"10.1016\/j.pharmthera.2009.06.005_bib80","doi-asserted-by":"crossref","first-page":"11706","DOI":"10.1016\/S0021-9258(19)38454-6","article-title":"The antiparallel pancreatic polypeptide fold in the binding of neuropeptide Y to Y1 and Y2 receptors","volume":"265","author":"Fuhlendorff","year":"1990","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib81","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1172\/JCI116395","article-title":"Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats","volume":"91","author":"Fujimoto","year":"1993","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib82","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1464-5491.1993.tb01995.x","article-title":"Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients","volume":"10","author":"Fukase","year":"1993","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib83","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1210\/jcem-57-3-488","article-title":"Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract","volume":"57","author":"Ghatei","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib84","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1037\/h0034870","article-title":"Cholecystokinin decreases food intake in rats","volume":"84","author":"Gibbs","year":"1973","journal-title":"J Comp Physiol Psychol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib85","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1055\/s-2007-1010817","article-title":"Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance","volume":"20","author":"Glaser","year":"1988","journal-title":"Horm Metab Res"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.06.005_bib86","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/oby.2006.180","article-title":"Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans","volume":"14","author":"Guo","year":"2006","journal-title":"Obesity (Silver Spring)"},{"issue":"5223","key":"10.1016\/j.pharmthera.2009.06.005_bib87","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.7624777","article-title":"Weight-reducing effects of the plasma protein encoded by the obese gene","volume":"269","author":"Halaas","year":"1995","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2009.06.005_bib88","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1530\/eje.0.151S071","article-title":"Novel analogs of ghrelin: physiological and clinical implications","volume":"151","author":"Halem","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib89","doi-asserted-by":"crossref","first-page":"E1010","DOI":"10.1152\/ajpendo.2000.278.6.E1010","article-title":"Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum","volume":"278","author":"Hansen","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib90","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF00404025","article-title":"Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans","volume":"34","author":"Hartter","year":"1991","journal-title":"Diabetologia"},{"issue":"36","key":"10.1016\/j.pharmthera.2009.06.005_bib91","doi-asserted-by":"crossref","first-page":"13174","DOI":"10.1073\/pnas.0404175101","article-title":"Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer","volume":"101","author":"Helmling","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib92","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000138122","article-title":"Variation of postprandial PYY 3-36 response following ingestion of differing macronutrient meals in obese females","volume":"52","author":"Helou","year":"2008","journal-title":"Ann Nutr Metab"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib93","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000201231","article-title":"Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients","volume":"56","author":"Herrmann","year":"1995","journal-title":"Digestion"},{"issue":"16","key":"10.1016\/j.pharmthera.2009.06.005_bib94","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","article-title":"Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial","volume":"282","author":"Heymsfield","year":"1999","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib95","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1254\/jphs.CRJ06002X","article-title":"Biological, physiological, and pharmacological aspects of ghrelin","volume":"100","author":"Hosoda","year":"2006","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib96","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0196-9781(81)80007-1","article-title":"Neuropeptides in the gut: quantification and characterization of cholecystokinin octapeptide-, bombesin- and vasoactive intestinal polypeptide-like immunoreactivities in the myenteric plexus of the guinea-pig small institute","volume":"2","author":"Hutchison","year":"1981","journal-title":"Peptides"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib97","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.peptides.2009.01.019","article-title":"Is desacyl ghrelin a modulator of food intake?","volume":"30","author":"Inhoff","year":"2009","journal-title":"Peptides"},{"issue":"38","key":"10.1016\/j.pharmthera.2009.06.005_bib98","doi-asserted-by":"crossref","first-page":"15069","DOI":"10.1073\/pnas.0706890104","article-title":"Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1","volume":"104","author":"Jang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2008.09.091","article-title":"A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db\/db mice","volume":"133","author":"Jin","year":"2009","journal-title":"J Control Release"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.06.005_bib101","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.2337\/diabetes.50.12.2779","article-title":"Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1","volume":"50","author":"Jong","year":"2001","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib102","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.clpt.6100272","article-title":"Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients","volume":"83","author":"Jordan","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib103","first-page":"393","article-title":"Fasting and postprandial plasma pancreatic polypeptide (PP) levels in obesity","volume":"8","author":"Jorde","year":"1984","journal-title":"Int J Obes"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib104","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gtc.2004.12.002","article-title":"Pharmacological therapies for obesity","volume":"34","author":"Kaplan","year":"2005","journal-title":"Gastroenterol Clin North Am"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib105","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib106","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/ajcn\/34.2.154","article-title":"C-terminal octapeptide of cholecystokinin decreases food intake in man","volume":"34","author":"Kissileff","year":"1981","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.06.005_bib107","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib108","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/gut.2004.061010","article-title":"Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats","volume":"55","author":"Kobelt","year":"2006","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib109","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1210\/en.2004-1266","article-title":"The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats","volume":"146","author":"Koda","year":"2005","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.06.005_bib110","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.2337\/diabetes.54.11.3198","article-title":"Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques","volume":"54","author":"Koegler","year":"2005","journal-title":"Diabetes"},{"issue":"6762","key":"10.1016\/j.pharmthera.2009.06.005_bib111","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib112","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/gut.39.5.661","article-title":"Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids","volume":"39","author":"Koop","year":"1996","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib113","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1172\/JCI4901","article-title":"The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight","volume":"103","author":"Kopin","year":"1999","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.06.005_bib114","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/oby.2006.179","article-title":"Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels","volume":"14","author":"Korner","year":"2006","journal-title":"Obesity"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00000658-195409000-00018","article-title":"An experimental evaluation of the nutritional importance of proximal and distal small intestine","volume":"140","author":"Kremen","year":"1954","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib116","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1164\/ajrccm.160.6.9902115","article-title":"Prognostic value of nutritional status in chronic obstructive pulmonary disease","volume":"160","author":"Landbo","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib117","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00221800","article-title":"Immunohistochemical localization of human pancreatic polypeptide (HPP) to a population of islet cells","volume":"156","author":"Larsson","year":"1975","journal-title":"Cell Tissue Res"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib118","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2337\/diabetes.29.6.428","article-title":"Low plasma levels of pancreatic polypeptide in obesity","volume":"29","author":"Lassmann","year":"1980","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib119","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1210\/jc.74.6.1405","article-title":"Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone","volume":"74","author":"Le Quellec","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.06.005_bib120","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1210\/jc.2004-2537","article-title":"Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy","volume":"90","author":"le Roux","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib121","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1210\/jc.2004-1216","article-title":"Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects","volume":"90","author":"le Roux","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib122","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1210\/en.2005-0972","article-title":"Attenuated peptide YY release in obese subjects is associated with reduced satiety","volume":"147","author":"le Roux","year":"2006","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib123","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/SLA.0b013e3180caa3e3","article-title":"Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass","volume":"246","author":"le Roux","year":"2007","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib124","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1172\/JCI111809","article-title":"Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction","volume":"75","author":"Liddle","year":"1985","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib125","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/0016-5085(94)90397-2","article-title":"Satiety effects of cholecystokinin in humans","volume":"106","author":"Lieverse","year":"1994","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib126","first-page":"123","article-title":"Plasma cholecystokinin and pancreatic polypeptide secretion in response to bombesin, meal ingestion and modified sham feeding in lean and obese persons","volume":"18","author":"Lieverse","year":"1994","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib127","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/gut.36.2.176","article-title":"Satiety effects of a physiological dose of cholecystokinin in humans","volume":"36","author":"Lieverse","year":"1995","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.06.005_bib128","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/ijo.2008.160","article-title":"The effects of pancreatic polypeptide on locomotor activity and food intake in mice","volume":"32","author":"Liu","year":"2008","journal-title":"Int J Obes (Lond)"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib129","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0167-0115(85)90204-6","article-title":"Abrogation of peripheral cholecystokinin-satiety in the capsaicin treated rat","volume":"11","author":"MacLean","year":"1985","journal-title":"Regul Pept"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib131","doi-asserted-by":"crossref","first-page":"R882","DOI":"10.1152\/ajpregu.2000.278.4.R882","article-title":"Cholecystokinin and leptin act synergistically to reduce body weight","volume":"278","author":"Matson","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib132","doi-asserted-by":"crossref","first-page":"R1368","DOI":"10.1152\/ajpregu.00080.2001","article-title":"Daily CCK injection enhances reduction of body weight by chronic intracerebroventricular leptin infusion","volume":"282","author":"Matson","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"6683","key":"10.1016\/j.pharmthera.2009.06.005_bib133","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/30666","article-title":"RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor","volume":"393","author":"McLatchie","year":"1998","journal-title":"Nature"},{"issue":"5 Pt 2","key":"10.1016\/j.pharmthera.2009.06.005_bib134","first-page":"R983","article-title":"Pancreatic polypeptide stimulates gastric acid secretion through a vagal mechanism in rats","volume":"269","author":"McTigue","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib135","unstructured":"MDRNA. (2008). MDRNA announces phase 2 trial of PYY(3-36) does not meet weight loss endpoint. MDRNA: Press Release. July 31st, 2008 Retrieved June 2nd, 2009, from http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=83674&p=irol-newsArticle&ID=1182214&highlight=PYY%20nasal%20spray"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib136","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.06.005_bib137","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/0026-0495(86)90218-0","article-title":"Fasting- and meal-stimulated peptide hormone concentrations before and after gastric surgery for morbid obesity","volume":"35","author":"Meryn","year":"1986","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-291X(91)91325-7","article-title":"Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents","volume":"179","author":"Moore","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"issue":"4 Pt 2","key":"10.1016\/j.pharmthera.2009.06.005_bib139","first-page":"R1245","article-title":"Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin","volume":"272","author":"Moran","year":"1997","journal-title":"Am J Physiol"},{"issue":"3 Pt 2","key":"10.1016\/j.pharmthera.2009.06.005_bib140","first-page":"R618","article-title":"Disordered food intake and obesity in rats lacking cholecystokinin A receptors","volume":"274","author":"Moran","year":"1998","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib141","doi-asserted-by":"crossref","first-page":"R384","DOI":"10.1152\/ajpregu.00535.2004","article-title":"Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys","volume":"288","author":"Moran","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib142","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0196-9781(91)90148-I","article-title":"Amylin decreases food intake in mice","volume":"12","author":"Morley","year":"1991","journal-title":"Peptides"},{"issue":"1 Pt 2","key":"10.1016\/j.pharmthera.2009.06.005_bib143","first-page":"R164","article-title":"Effect of competitive antagonism of NO synthetase on weight and food intake in obese and diabetic mice","volume":"266","author":"Morley","year":"1994","journal-title":"Am J Physiol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib144","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1378\/chest.128.3.1187","article-title":"Treatment of cachexia with ghrelin in patients with COPD","volume":"128","author":"Nagaya","year":"2005","journal-title":"Chest"},{"issue":"6817","key":"10.1016\/j.pharmthera.2009.06.005_bib145","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35051587","article-title":"A role for ghrelin in the central regulation of feeding","volume":"409","author":"Nakazato","year":"2001","journal-title":"Nature"},{"issue":"3 Pt 2","key":"10.1016\/j.pharmthera.2009.06.005_bib146","first-page":"R910","article-title":"GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans","volume":"277","author":"Naslund","year":"1999","journal-title":"Am J Physiol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib147","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1079\/BJN20031064","article-title":"Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects","volume":"91","author":"Naslund","year":"2004","journal-title":"Br J Nutr"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib148","unstructured":"National Institutes of Health Clinical Center. (2009). The effects of exenatide (Byetta) on energy expenditure and weight loss in non-diabetic obese subjects. ClinicalTrials.gov Retrieved June 3rd, 2009, from http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00856609?term=byetta+obesity&rank=1"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib149","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.physbeh.2009.02.024","article-title":"Peptide YY: food for thought","volume":"97","author":"Neary","year":"2009","journal-title":"Physiol Behav"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib150","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1210\/jc.2003-031768","article-title":"Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial","volume":"89","author":"Neary","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.06.005_bib151","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1210\/en.2005-0237","article-title":"Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively","volume":"146","author":"Neary","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib152","unstructured":"Novo Nordisk. (2008). Significant weight loss sustained in obese people treated with liraglutide for one year. Nova Nordisk: Press Release June 16, 2008 Retrieved June 3rd, 2009, from http:\/\/www.novonordisk.com\/investors\/sea\/sea.asp?sShowNewsItemGuID=34d7e084-1d6b-4b78-bb9e-f0bf70920b0a&sShowLanguageCode=en-GB&sSearchText=Liraglutide+AND+obesity"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib153","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diabetes.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans","volume":"43","author":"Orskov","year":"1994","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.06.005_bib154","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/00365529609009147","article-title":"Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day","volume":"31","author":"Orskov","year":"1996","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib155","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3346\/jkms.2007.22.3.436","article-title":"Peptide YY, cholecystokinin, insulin and ghrelin response to meal did not change, but mean serum levels of insulin is reduced in children with Prader\u2013Willi syndrome","volume":"22","author":"Paik","year":"2007","journal-title":"J Korean Med Sci"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib156","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1210\/jc.87.4.1797","article-title":"A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal","volume":"87","author":"Parkinson","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib157","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.neuroimage.2008.09.047","article-title":"Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI)","volume":"44","author":"Parkinson","year":"2009","journal-title":"Neuroimage"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib158","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.npep.2004.05.007","article-title":"Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts","volume":"38","author":"Pedrazzini","year":"2004","journal-title":"Neuropeptides"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.06.005_bib159","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1038\/oby.2007.323","article-title":"The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England","volume":"15","author":"Perrio","year":"2007","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib160","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0031-9384(82)90230-X","article-title":"C-terminal octapeptide of cholecystokinin decreases food intake in obese men","volume":"29","author":"Pi-Sunyer","year":"1982","journal-title":"Physiol Behav"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib161","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1210\/jc.84.1.3","article-title":"Therapeutic controversy: obesity\u2014a modern-day epidemic","volume":"84","author":"Pi-Sunyer","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.06.005_bib162","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.ijo.0802696","article-title":"Effects of PYY[3-36] in rodent models of diabetes and obesity","volume":"28","author":"Pittner","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"7943","key":"10.1016\/j.pharmthera.2009.06.005_bib163","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(75)90297-4","article-title":"Identification of cholecystokinin-secreting cells","volume":"2","author":"Polak","year":"1975","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib164","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gut.38.6.916","article-title":"Attenuated GLP-1 secretion in obesity: cause or consequence?","volume":"38","author":"Ranganath","year":"1996","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib165","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1463-1326.2006.00589.x","article-title":"Long-term effects of exenatide therapy over 82weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus","volume":"8","author":"Ratner","year":"2006","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib166","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1210\/jc.86.1.251","article-title":"The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33","volume":"86","author":"Rehfeld","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib167","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/MPG.0b013e3180406a24","article-title":"Fasting glucagon-like peptide-1 and its relation to insulin in obese children before and after weight loss","volume":"44","author":"Reinehr","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib168","doi-asserted-by":"crossref","first-page":"R1833","DOI":"10.1152\/ajpregu.2001.281.6.R1833","article-title":"Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP","volume":"281","author":"Riediger","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4 Pt 2","key":"10.1016\/j.pharmthera.2009.06.005_bib169","first-page":"R501","article-title":"Capsaicin pretreatment attenuates suppression of food intake by cholecystokinin","volume":"248","author":"Ritter","year":"1985","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib170","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/380403a0","article-title":"Characterization and inhibition of a cholecystokinin-inactivating serine peptidase","volume":"380","author":"Rose","year":"1996","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.06.005_bib171","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrg1432","article-title":"Pharmacogenetics and drug development: the path to safer and more effective drugs","volume":"5","author":"Roses","year":"2004","journal-title":"Nat Rev Genet"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib172","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/clpt.2008.192","article-title":"Stimulation of cholecystokinin-A receptors with Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake","volume":"85","author":"Roses","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib173","doi-asserted-by":"crossref","unstructured":"Roth, J., Coffey, T., Jodka, C., Maier, H., Athanacio, J., Mack, C., et al. (2007). Combination therapy with amylin and PYY[3 36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology, en.2007-0898.","DOI":"10.1210\/en.2007-0898"},{"issue":"20","key":"10.1016\/j.pharmthera.2009.06.005_bib174","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.0706473105","article-title":"Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies","volume":"105","author":"Roth","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib175","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1210\/en.141.2.850","article-title":"Amylin: a novel action in the brain to reduce body weight","volume":"141","author":"Rushing","year":"2000","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib176","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1172\/JCI108992","article-title":"Vagal, cholinergic regulation of pancreatic polypeptide secretion","volume":"61","author":"Schwartz","year":"1978","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.06.005_bib177","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm1196-1254","article-title":"Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene","volume":"2","author":"Scrocchi","year":"1996","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib178","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1210\/en.2005-0993","article-title":"Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice","volume":"147","author":"Shearman","year":"2006","journal-title":"Endocrinology"},{"issue":"7113","key":"10.1016\/j.pharmthera.2009.06.005_bib179","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nature05143","article-title":"Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism","volume":"443","author":"Shen","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib180","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1210\/jc.87.1.240","article-title":"Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion","volume":"87","author":"Shiiya","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.06.005_bib181","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1373\/clinchem.2005.054908","article-title":"Circulating peptide YY concentrations are higher in preterm than full-term infants and correlate negatively with body weight and positively with serum ghrelin concentrations","volume":"51","author":"Siahanidou","year":"2005","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib182","doi-asserted-by":"crossref","first-page":"E443","DOI":"10.1152\/ajpendo.2001.280.3.E443","article-title":"Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas","volume":"280","author":"Silvestre","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib183","doi-asserted-by":"crossref","first-page":"E1062","DOI":"10.1152\/ajpendo.00450.2006","article-title":"Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects","volume":"292","author":"Sloth","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib184","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1371\/journal.pmed.0010062","article-title":"Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index","volume":"1","author":"Taheri","year":"2004","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.06.005_bib185","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1210\/en.2002-220268","article-title":"Ghrelin stimulates GH but not food intake in arcuate nucleus ablated rats","volume":"143","author":"Tamura","year":"2002","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.06.005_bib186","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1210\/jc.2004-0835","article-title":"Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader\u2013Willi syndrome","volume":"89","author":"Tan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4 Pt 2","key":"10.1016\/j.pharmthera.2009.06.005_bib187","first-page":"R848","article-title":"Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats","volume":"271","author":"Tang-Christensen","year":"1996","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib188","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/dmrr.698","article-title":"Slow versus fast proteins in the stimulation of beta-cell response and the activation of the entero-insular axis in type 2 diabetes","volume":"23","author":"Tessari","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.06.005_bib189","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1172\/JCI25811","article-title":"Ghrelin action in the brain controls adipocyte metabolism","volume":"116","author":"Theander-Carrillo","year":"2006","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib190","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0889-8529(03)00066-5","article-title":"Obesity and pharmacologic therapy","volume":"32","author":"Thearle","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib191","unstructured":"Thiakis Limited. (2008). Novel therapy for treatment of obesity enters clinical trials. Thaikis-Limited: Press Release March 12, 2008 Retrieved June 3rd, 2009, from http:\/\/www.adventventures.com\/news\/story.cfm?ref=281"},{"issue":"Suppl 2","key":"10.1016\/j.pharmthera.2009.06.005_bib192","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1002\/(SICI)1096-9136(199706)14:2+<S29::AID-DIA401>3.3.CO;2-S","article-title":"Amylin release during oral glucose tolerance test","volume":"14","author":"Thomaseth","year":"1997","journal-title":"Diabet Med"},{"issue":"Pt 1","key":"10.1016\/j.pharmthera.2009.06.005_bib193","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1113\/jphysiol.2008.164012","article-title":"Nutritional regulation of glucagon-like peptide-1 secretion","volume":"587","author":"Tolhurst","year":"2009","journal-title":"J Physiol"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.06.005_bib194","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1139\/y80-223","article-title":"Human pancreatic polypeptide: studies of fasting and postprandial plasma concentrations","volume":"58","author":"Track","year":"1980","journal-title":"Can J Physiol Pharmacol"},{"issue":"6806","key":"10.1016\/j.pharmthera.2009.06.005_bib195","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/35038090","article-title":"Ghrelin induces adiposity in rodents","volume":"407","author":"Tschop","year":"2000","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.06.005_bib196","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2337\/diabetes.50.4.707","article-title":"Circulating ghrelin levels are decreased in human obesity","volume":"50","author":"Tschop","year":"2001","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.06.005_bib197","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/jn\/129.8.1503","article-title":"The role of apolipoprotein A-IV in food intake regulation","volume":"129","author":"Tso","year":"1999","journal-title":"J Nutr"},{"issue":"6560","key":"10.1016\/j.pharmthera.2009.06.005_bib198","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib199","first-page":"1","article-title":"Overweight and obesity: a major public health issue","volume":"16","author":"U.S. Department of Health and Human Services","year":"2001","journal-title":"Prev Rep"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib200","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0016-5085(99)70293-3","article-title":"Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice","volume":"117","author":"Ueno","year":"1999","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib201","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1152\/ajpregu.00234.2007","article-title":"Leptin extends the anorectic effects of chronic PYY(3-36) administration in ad libitum-fed rats","volume":"295","author":"Unniappan","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.06.005_bib202","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/jc.86.9.4382","article-title":"A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans","volume":"86","author":"Verdich","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.06.005_bib203","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/sj.ijo.0801655","article-title":"The role of postprandial releases of insulin and incretin hormones in meal-induced satiety\u2014effect of obesity and weight reduction","volume":"25","author":"Verdich","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.06.005_bib204","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.domaniend.2006.05.005","article-title":"Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs","volume":"33","author":"Vizcarra","year":"2007","journal-title":"Domest Anim Endocrinol"},{"issue":"5 Pt 2","key":"10.1016\/j.pharmthera.2009.06.005_bib205","first-page":"R776","article-title":"Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats","volume":"246","author":"West","year":"1984","journal-title":"Am J Physiol"},{"issue":"13","key":"10.1016\/j.pharmthera.2009.06.005_bib206","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","article-title":"Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib207","unstructured":"WHO (2006) Obesity and overweight: fact sheet n. 311 World Health Organisation Retrieved on June 15, 2009, from http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/index.html"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.06.005_bib208","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1210\/en.2003-1059","article-title":"Vagotomy dissociates short- and long-term controls of circulating ghrelin","volume":"144","author":"Williams","year":"2003","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib209","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0167-0115(92)90007-H","article-title":"Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal","volume":"39","author":"Wisen","year":"1992","journal-title":"Regul Pept"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.06.005_bib210","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1210\/en.141.11.4325","article-title":"The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion","volume":"141","author":"Wren","year":"2000","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.06.005_bib211","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1210\/jc.86.12.5992","article-title":"Ghrelin enhances appetite and increases food intake in humans","volume":"86","author":"Wren","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2009.06.005_bib212","unstructured":"Wyeth Pharmaceuticals. (2008). Wyeth Pharmaceuticals acquires Thiakis Limited. Wyeth Pharmaceuticals: Press Release December 18th, 2008 Retrieved June 3rd, 2009, from http:\/\/www.wyeth.com\/news?nav=display&navTo=\/wyeth_html\/home\/news\/pressreleases\/2009\/1229603323725.html"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.06.005_bib213","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.2337\/diabetes.54.8.2390","article-title":"Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial","volume":"54","author":"Wynne","year":"2005","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.06.005_bib214","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.ijo.0803344","article-title":"Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial","volume":"30","author":"Wynne","year":"2006","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib215","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF02828131","article-title":"Interaction of dietary composition and PYY gene expression in diet-induced obesity in rats","volume":"25","author":"Yang","year":"2005","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.06.005_bib216","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2008.01.017","article-title":"Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone","volume":"132","author":"Yang","year":"2008","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.06.005_bib217","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMra012586","article-title":"Obesity","volume":"346","author":"Yanovski","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.06.005_bib218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-0495(96)90192-4","article-title":"Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake","volume":"45","author":"Young","year":"1996","journal-title":"Metabolism"},{"issue":"6505","key":"10.1016\/j.pharmthera.2009.06.005_bib219","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homologue","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.pharmthera.2009.06.005_bib220","doi-asserted-by":"crossref","first-page":"22418","DOI":"10.1074\/jbc.M212355200","article-title":"The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38)","volume":"278","author":"Zhu","year":"2003","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.06.005_bib221","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.06.005_bib222","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1210\/jcem-52-6-1264","article-title":"Blunted pancreatic polypeptide responses in children with obesity of Prader\u2013Willi syndrome","volume":"52","author":"Zipf","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.06.005_bib223","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1210\/jcem-57-5-1074","article-title":"Pancreatic polypeptide responses to protein meal challenges in obese but otherwise normal children and obese children with Prader\u2013Willi syndrome","volume":"57","author":"Zipf","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"issue":"35","key":"10.1016\/j.pharmthera.2009.06.005_bib224","doi-asserted-by":"crossref","first-page":"13226","DOI":"10.1073\/pnas.0605376103","article-title":"Vaccination against weight gain","volume":"103","author":"Zorrilla","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2009.06.005_bib225","first-page":"13","article-title":"Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome","volume":"58","author":"Zwirska-Korczala","year":"2007","journal-title":"J Physiol Pharmacol"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809001338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809001338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T18:48:55Z","timestamp":1633632535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725809001338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":224,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0163725809001338"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2009.06.005","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}